Main Article Content
The current study was focused on patients with Colorectal Cancer between the ages of 26–82years. The objective of this study to determine the interleukin (IL-17) level and CD33 expression status in patients with Colorectal Cancer. A total of 60 out of (40 patients and 20 control groups) were collected from gastroenterology and liver diseases teaching hospital from March 2018–May 2018, Iraq. The results show Median IL-17 was significantly higher in study group than in control group (plessthan 0.001), 12.13 (9.73) pg/ml versus 0.41 (0.67) pg/ml, and Median CD33 was significantly higher in study group than in control group (plessthan 0.001), 73.00 (5.0) % versus 4.50 (3.75) %.